Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $5.8 million.

  • Iovance Biotherapeutics' Amortizatization of Intangibles rose 545.45% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 2120.29%. This contributed to the annual value of $21.2 million for FY2024, which is 8105.89% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Amortizatization of Intangibles stood at $5.8 million, which was up 545.45% from $5.7 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Amortizatization of Intangibles peaked at $5.8 million during Q3 2025, and registered a low of $1.9 million during Q2 2023.
  • Its 3-year average for Amortizatization of Intangibles is $4.5 million, with a median of $5.4 million in 2025.
  • In the last 5 years, Iovance Biotherapeutics' Amortizatization of Intangibles surged by 18947.37% in 2024 and then surged by 363.64% in 2025.
  • Iovance Biotherapeutics' Amortizatization of Intangibles (Quarter) stood at $2.9 million in 2023, then soared by 92.71% to $5.5 million in 2024, then increased by 5.42% to $5.8 million in 2025.
  • Its Amortizatization of Intangibles was $5.8 million in Q3 2025, compared to $5.7 million in Q2 2025 and $5.4 million in Q1 2025.